Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.
Ronan J KellyJaffer A AjaniJaroslaw KuzdzalThomas ZanderEric Van CutsemGuillaume PiessenGuillermo MendezJosephine FelicianoSatoru MotoyamaAstrid LièvreHope UronisElena ElimovaCecile GrootscholtenKaren GeboesSyed ZafarStephanie SnowAndrew H KoKynan FeeneyMichael SchenkerPiotr KoconJenny ZhangLili ZhuMing LeiPrianka SinghKaoru KondoJames M ClearyMarkus Moehlernull nullPublished in: The New England journal of medicine (2021)
Among patients with resected esophageal or gastroesophageal junction cancer who had received neoadjuvant chemoradiotherapy, disease-free survival was significantly longer among those who received nivolumab adjuvant therapy than among those who received placebo. (Funded by Bristol Myers Squibb and Ono Pharmaceutical; CheckMate 577 ClinicalTrials.gov number, NCT02743494.).